OncoAssure Ltd, an Irish medical diagnostic company, recently published new data in the British Journal of Urology International Compass, which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

The new study, a collaboration by researchers from OncoAssure, University College Dublin, and Lund University, Sweden illustrates how OncoAssure Prostate, when tested on prostate cancer biopsy specimens, improves clinicians’ ability to estimate the likelihood of aggressive cancer compared to using standard clinical and pathological information.

The study demonstrated that integrating OncoAssure Prostate results with standard clinical and pathological information can substantially improve prognostic accuracy. Patients with higher OncoAssure Prostate risk scores were more likely to experience cancer recurrence, whereas men with lower risk scores were identified as suitable candidates for active surveillance.

OncoAssure now plans to launch the OncoAssure Prostate test in the US market in collaboration with DiaCarta Inc through DiaCarta’s ISO and CAP/CLIA Certified laboratory service, in Pleasanton, California.

OncoAssure was co-founded by Des O’Leary and Prof William Gallagher in 2021 and is headquartered at NovaUCD in Dublin. The study was carried out with funding support from Research Ireland, OncoAssure Ltd, Swedish Cancer Society and Swedish Scientific Council.